BMS to build new cell therapy manufacturing site in Europe
US pharma major Bristol Myers Squibb (NYSE: BMS) is expanding its global manufacturing footprint by investing in a new cell therapy manufacturing site in the Netherlands.
The site will be based in the Leiden Bio Science Park, the region’s growing life sciences hub, which is conveniently located near transportation to ship patient cells. Construction is slated to begin later this year.
The facility – which will be BMS’ fifth state-of-the-art site globally and first in Europe – will have capabilities for multi-product cell therapy manufacturing, including potentially liso-cel and ide-cel (pending regulatory approval). The facility will also leverage innovative technology, the latest manufacturing equipment and advanced digital systems to deliver critical cell therapies to patients in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze